Abstract 1938P
Background
The prognosis for young patients with papillary thyroid cancer is usually good unless distant metastases occur. Lung metastasis is one of the most common distant metastases of thyroid cancer, but lacks an effective way to predict it. Our aim was to develop a nomogram to predict the possibility of lung metastases in patients with papillary thyroid cancer under 55 years old, considering the genetic background.
Methods
243 patients with papillary thyroid cancer under 55 years old were collected from January 2017 to June 2020 and randomly divided (7:3) into the training (n=170) and validation (n=73) groups. Univariate and multivariate binary logistic regression analyses were conducted, based on which a nomogram related to the risk of lung metastases of thyroid cancer was built in the training group. The nomogram was evaluated by calibration curves and decision curve analysis (DCA), the concordance index (C-index) and area under the receiver operating characteristic (ROC) curve (AUC) in the training and validation groups, respectively.
Results
T stage, Single-side invasion, TERT mutation and BRAF mutation were the independent prognostic factors for the construction of the nomogram. The C-index of the nomogram was 0.89 and 0.88 in the training and validation groups, respectively. The AUC, DAC, and calibration curves for nomogram showed satisfactory results. The cut-off value was 0.229, with a sensitivity of 0.829 and a specificity of 0.793.
Conclusions
A nomogram with good predictive capability has been established and validated, which may do a favor to predict lung metastases of young patients with papillary thyroid cancer in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The science and technology innovation Program of Hunan Province (2023SK4043).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1475TiP - Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced G/GEJ cancer: A phase Ib/II clinical trial (FUNCTION)
Presenter: Bei-Bei Chen
Session: Poster session 18
1505P - Exploratory biomarker analysis of the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) Gem-nabPac chemotherapy (CTX) in resectable PDAC patients (rPDAC Pts)
Presenter: Anton Lahusen
Session: Poster session 18
1506P - ctDNA testing based on deep NGS predicts treatment efficacy and prognosis in advanced pancreatic cancer patients
Presenter: Tingting You
Session: Poster session 18
1507P - Revolutionizing clinical trials: Harnessing artificial intelligence for optimized phase III studies in pancreatic cancer
Presenter: Marie-Edith Bonneterre
Session: Poster session 18
1509P - Cytokines and ductal pancreatic adenocarcinoma: Exploring their relationship with prognosis and molecular subtypes
Presenter: Laura Gutierrez Sainz
Session: Poster session 18
1510P - Exploration of circulating free bacterial DNA as a biomarker for therapy response in metastatic and locally advanced pancreatic cancer patients treated with systemic chemotherapy
Presenter: Sai Surendran
Session: Poster session 18
1511P - The influence of intratumoral bacteria and peri-operative antibiotic treatment on the outcome of resected pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapy
Presenter: Steffen Ormanns
Session: Poster session 18
1512P - The role of pancreaticoduodenectomy for octogenarians with pancreatic cancer
Presenter: Keita Sonoda
Session: Poster session 18
1513P - Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)
Presenter: Omali Pitiyarachchi
Session: Poster session 18